Mohd Naeem Mohd Nawi1, Tikfu Gee2,3,4, Lim Syu Yu2,3,4, Elina Tsen Poh Yue2,3,4, Zubaidah Nor Hanipah5, Nur Azlin Zainal Abidin1, Tan You Zhuan1, Farah Huda Mohkiar1, Liyana Ahmad Zamri1, Haron Ahmad6, Mohd Shazli Draman6, Noorizatul Syahira Yusaini1 and Fazliana Mansor1*
1. Nutrition, Metabolism and Cardiovascular Research Centre, Institute for Medical Research, National Institutes of Health, Ministry of Health Malaysia, Setia Alam, Shah Alam 40170, Malaysia
2. iHeal Medical Centre, Mid Valley City, Lingkaran Syed Putra, Kuala Lumpur 59200, Malaysia
3. Sunway Velocity Medical Centre, 55100 Kuala Lumpur, Malaysia
4. Sunway Medical Centre, Bandar Sunway 47500, Malaysia
5. Department of Surgery, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400 Serdang, Malaysia
6. KPJ Damansara Specialist Hospital, Damansara Utama, 47400 Petaling Jaya, Malaysia
*Corresponding author: Fazliana Mansor.
ABSTRACT
INTRODUCTION: The global diabetes epidemic, projected to affect 783 million adults by 2045, disproportionately impacts Malaysia where prevalence exceeds 15%. Traditional risk factors like body mass index (BMI) and glycated hemoglobin (HbA1c) inadequately capture early metabolic dysfunction in obesity-driven type 2 diabetes (T2D). Metabolomics improves early T2D prediction beyond traditional risk factors by identifying and quantifying a wide array of small-molecule metabolites that reflect early metabolic dysfunction years before clinical onset.
OBJECTIVE(S): To identify metabolomic signatures for early diagnosis, risk prediction, and personalized treatment of obesity and T2D, independent of traditional clinical risk factors.
MATERIALS & METHODS: A multicenter cross-sectional study analysed fasting plasma from 137 participants: 111 obese patients (BMI ≥25 kg/m², Asian criteria) stratified by diabetes status (obese only/prediabetes/diabetes via HbA1c) were recruited from five centers: iHEAL Medical Centre (Kuala Lumpur), Sunway Medical Centre Velocity (Kuala Lumpur), Sunway Medical Centre (Selangor), KPJ Damansara Specialist Hospital (Kuala Lumpur) while 26 healthy controls were recruited from Institute for Medical Research (IMR), National Institutes of Health (NIH) (Setia Alam). Metabolites were profiled using 1H-Nuclear Magnetic Resonance (NMR) spectroscopy. Data were processed via MetaboAnalyst 6.0, employing analysis of variance (ANOVA), fold-change analysis, orthogonal partial least squares-discriminant analysis (OPLS-DA), hierarchical clustering and correlation heatmaps.
RESULTS: Obese participants exhibited marked upregulation of fucose, 3-aminoisobutyrate, acetoacetate, and 3-hydroxybutyrate (>2.6-fold vs. controls), with peak elevations in diabetic obesity. OPLS-DA further identified T2D-discriminatory signatures, designating putrescine, glycine, glucose, and trimethylamine N-oxide (TMAO) as key classifiers for T2D. Hierarchical clustering analysis identified four distinct metabolite clusters, with Cluster 1 (glycine, 1,6-anhydro-β-D-glucose, myo-inositol, π-methylhistidine, 4-hydroxyphenylacetate, 3-hydroxyphenylacetate, taurine, glucose, and TMAO) demonstrating strong positive intercorrelations and the most significant association with obesity-driven T2D severity.
CONCLUSION: We identified a robust metabolomic signature (Cluster 1: glycine, 1,6-anhydro-β-D-glucose, myo-inositol, π-methylhistidine, hydroxyphenylacetates, taurine, glucose, TMAO) strongly associated with obesity-driven T2D severity. While these findings enhance our understanding of metabolic pathways in obesity-driven T2D, future longitudinal studies are warranted to validate these metabolites as early biomarkers for improved risk prediction.
KEYWORDS: Metabolomics, T2D, NMR, Biomarkers, Obesity


